A new Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT01938495) titled “Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)” is examining the efficacy of DPS compared to standard of care in patients with ALS,…
Search results for:
Dr. Jonathan Kipnis, Ph.D., professor of neuroscience and Director of the Center for Brain Immunology and Glia (BIG) at the University of Virginia Medical School, and his research team from the Laboratory of Cellular and Molecular Neuroimmunology, made an important discovery in the field…
Biopharmaceutical company MediciNova, Inc. announced that an abstract on the company’s ongoing clinical trial of MN-166 (ibudilast) to address amyotrophic lateral sclerosis (ALS) has been accepted for presentation at the American Academy of Neurology (AAN) 67th Annual Meeting, which will take place on…
Now in its second year as a Gold-level national partner, BAYADA Home Health Care will be supporting several initiatives by The ALS Association, including Walk to Defeat ALS to raise funds from events all across the nation in the fight against amyotrophic lateral sclerosis (ALS).
A research team led by Diego Minciacchi of the University of Florence in Italy identified a population of neurons that might explain the cognitive alterations antecedent to motor symptoms in Amyotrophic Lateral Sclerosis (ALS). The study entitled, “Increased anxiety-like behavior and selective learning impairments are concomitant to…
The national nonprofit United Spinal Association is advocating along with the Washington DC Taxicab Commission (DCTC) for the implementation of the DC Taxicab Service Improvement Amendment Act of 2012’s regulations and an increase in taxis able to carry wheelchairs. The implementation of the rule may impact the lives of people suffering from…
BioMotiv is a drug advancement accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle working on breakthrough discoveries and new therapeutics that have the potential to address unmet clinical needs. Recently, the accelerator announced the creation of a platform company, OptiKira, that will…
A research team from the University of Wisconsin-Madison Waisman Center led by Su Chun Zhang, established a simple model in mice to investigate the role of human astrocytes in neurologic diseases such as Amyotrophic Lateral Sclerosis (ALS), Rett Syndrome and Huntington’s disease. The study entitled…
Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present…
Biopharmaceutical company Genervon recently reported observing improvements in a 46-year-old-man with advanced amyotrophic lateral sclerosis (ALS) taking the Company’s drug candidate GM604. The patient showed increased speech, swallowing and suction capabilities after a 12-week treatment. The drug, which has yet to be approved by the…